Group B *Streptococcus* (GBS) remains the most common cause of neonatal sepsis and meningitis in the world.\(^1\)

In 2002, the CDC recommended universal GBS antenatal screening along with intrapartum antibiotic prophylaxis (IAP). The incidence of the early onset disease (EOD) was subsequently reduced by around 80\%.\(^2,3\)

However, and despite these improvements, there are still 52 to 82% of newborns infected by GBS who were born from mothers screened negative at 35-37 weeks of pregnancy and thus did not receive IAP.\(^4,5,6\)

Conversely, there are also “false positive screening” obtained from women colonized with GBS who are no longer carriers at the moment of labor and will unnecessarily receive IAP.

In 2013, a group of experts have published European guidelines\(^7\) to define the best strategy for reducing more efficiently the risk of GBS neonatal diseases. The recommendation was the administration of IAP based on a universal intrapartum GBS screening using a rapid real-time test.

**EASY-TO-USE TEST FOR INTRAPARTUM GBS SCREENING**

GenePOC GBS DS is a molecular easy-to-use assay adapted for Point of Care testing, which provide a timely and accurate evaluation of the woman’s GBS colonization status at the time of delivery. GenePOC GBS DS result will help to better control the risk of GBS transmission to the newborn, and consequently help to lower mortality and morbidity.

GenePOC GBS DS for the identification of intrapartum Group B *Streptococcus* colonization:

- Easy-to-use direct test from vaginal/rectal swab
- Results available when it matters: Improve antibiotic stewardship by not treating women who do not need it.
- Compliant with 2013 European consensus\(^7\)

**TEST PERFORMANCE**\(^*\)

<table>
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensitivity</td>
<td>96.4%</td>
</tr>
<tr>
<td>Specificity</td>
<td>89.9%</td>
</tr>
<tr>
<td>Negative Predictive Value (NPV)</td>
<td>98.6%</td>
</tr>
<tr>
<td>Positive Predictive Value (PPV)</td>
<td>77.5%</td>
</tr>
</tbody>
</table>

\(^*\)Performances compared to standard culture

**REVOGENE**

- Easy implementation
- Simple 3-steps workflow
- Small footprint
- Highly reproducible results
THE GENEPOC ADVANTAGES

- EASY-TO-USE: 1 minute hands-on time
- FLEXIBLE: Adapts to your throughput, allowing up to 8 samples in one run of 70 minutes
- ACCURATE: Real-time PCR technology
- USER-FRIENDLY: Intuitive graphical interface
- DATA MANAGEMENT: Bi-directional LIS connectivity
- SMALL FOOTPRINT: Fully integrated and compact system
- QUALITY ASSURANCE: Embedded process control to monitor sample processing and ensure optimal quality
- WASTE MINIMIZATION: Small consumable size resulting in significant reduction of medical waste and associated cost

FROM SAMPLE TO RESULTS IN 3 STEPS

1. Discharge sample
2. Load sample into the PIE
3. Place PIE into instrument and start

FINAL RESULTS: Within 70 minutes

REFERENCES

ORDERING INFORMATION

<table>
<thead>
<tr>
<th>Cat No</th>
<th>Name</th>
<th>Tests/Kit</th>
</tr>
</thead>
<tbody>
<tr>
<td>131852</td>
<td>GenePOC™ GBS DS</td>
<td>24</td>
</tr>
</tbody>
</table>

CONTACT INFORMATION

To find your local distributor contact, please visit our website at: www.genepoc-diagnostics.com/contact and ask for a presentation of the GenePOC system.

VISION: saving lives by “bringing the lab to the patient”
MISSION: to empower healthcare professionals and patients with affordable, simple, and rapid Point of Care (POC) molecular diagnostic tests for infectious diseases

ABOUT THE COMPANY

CONTACT INFORMATION

GenePOC Inc.
360 rue Franquet, Porte 3
Parc Technologique de Québec
Québec QC G1P 4N3 Canada

info@genepoc.ca
www.genepoc-diagnostics.com
T +1 418 650 3535